D R Sullivan1, L Ganzini2, J P Duckart2, A Lopez-Chavez3, M E Deffebach4, S M Thielke5, C G Slatore6. 1. Health Services Research & Development, Portland Veterans Affairs Medical Center, Portland, OR, USA; Division of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA. Electronic address: sullivad@ohsu.edu. 2. Health Services Research & Development, Portland Veterans Affairs Medical Center, Portland, OR, USA. 3. Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA. 4. Division of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA; Section of Pulmonary & Critical Care Medicine, Portland Veterans Affairs Medical Center, Portland, OR, USA. 5. Departments of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Geriatric Research, Education, and Clinical Center, Puget Sound Veterans Affairs Medical Center, Seattle, Washington, USA. 6. Health Services Research & Development, Portland Veterans Affairs Medical Center, Portland, OR, USA; Division of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA; Section of Pulmonary & Critical Care Medicine, Portland Veterans Affairs Medical Center, Portland, OR, USA.
Abstract
AIMS: Among lung cancer patients, depression has been associated with increased mortality, although the mechanisms are unknown. We evaluated the association of depression with mortality and receipt of cancer therapies among depressed veterans with lung cancer. MATERIALS AND METHODS: A retrospective, cohort study of lung cancer patients in the Veterans Affairs-Northwest Health Network from 1995 to 2010. Depression was defined by ICD-9 coding within 24 months before lung cancer diagnosis. Multivariable Cox proportional analysis and logistic regression were used. RESULTS: In total, 3869 lung cancer patients were evaluated; 14% had a diagnosis of depression. A diagnosis of depression was associated with increased mortality among all stage lung cancer patients (hazard ratio = 1.14, 95% confidence interval: 1.03-1.27, P = 0.01). Among early-stage (I and II) non-small cell lung cancer (NSCLC) patients, the hazard ratio was 1.37 (95% confidence interval: 1.12-1.68, P = 0.003). There was no association of depression diagnosis with surgery (odds ratio = 0.83, 95% confidence interval: 0.56-1.22, P = 0.34) among early-stage NSCLC patients. A depression diagnosis was not associated with mortality (hazard ratio = 1.02, 95% confidence interval: 0.89-1.16, P = 0.78) or chemotherapy (odds ratio = 1.07, 95% confidence interval: 0.83-1.39, P = 0.59) or radiation (odds ratio = 1.04, 95% confidence interval: 0.81-1.34, P = 0.75) receipt among advanced-stage (III and IV) NSCLC patients. Increased utilisation of health services for depression was associated with increased mortality among depressed patients. CONCLUSIONS: Depression is associated with increased mortality in lung cancer patients and this association is higher among those with increased measures of depression care utilisation. Differences in lung cancer treatment receipt are probably not responsible for the observed mortality differences between depressed and non-depressed patients. Clinicians should recognise the significant effect of depression on lung cancer survival.
AIMS: Among lung cancerpatients, depression has been associated with increased mortality, although the mechanisms are unknown. We evaluated the association of depression with mortality and receipt of cancer therapies among depressed veterans with lung cancer. MATERIALS AND METHODS: A retrospective, cohort study of lung cancerpatients in the Veterans Affairs-Northwest Health Network from 1995 to 2010. Depression was defined by ICD-9 coding within 24 months before lung cancer diagnosis. Multivariable Cox proportional analysis and logistic regression were used. RESULTS: In total, 3869 lung cancerpatients were evaluated; 14% had a diagnosis of depression. A diagnosis of depression was associated with increased mortality among all stage lung cancerpatients (hazard ratio = 1.14, 95% confidence interval: 1.03-1.27, P = 0.01). Among early-stage (I and II) non-small cell lung cancer (NSCLC) patients, the hazard ratio was 1.37 (95% confidence interval: 1.12-1.68, P = 0.003). There was no association of depression diagnosis with surgery (odds ratio = 0.83, 95% confidence interval: 0.56-1.22, P = 0.34) among early-stage NSCLCpatients. A depression diagnosis was not associated with mortality (hazard ratio = 1.02, 95% confidence interval: 0.89-1.16, P = 0.78) or chemotherapy (odds ratio = 1.07, 95% confidence interval: 0.83-1.39, P = 0.59) or radiation (odds ratio = 1.04, 95% confidence interval: 0.81-1.34, P = 0.75) receipt among advanced-stage (III and IV) NSCLCpatients. Increased utilisation of health services for depression was associated with increased mortality among depressedpatients. CONCLUSIONS:Depression is associated with increased mortality in lung cancerpatients and this association is higher among those with increased measures of depression care utilisation. Differences in lung cancer treatment receipt are probably not responsible for the observed mortality differences between depressed and non-depressedpatients. Clinicians should recognise the significant effect of depression on lung cancer survival.
Authors: Jacob E Berchuck; Craig S Meyer; Ning Zhang; Caroline M Berchuck; Neil N Trivedi; Beth Cohen; Sunny Wang Journal: JAMA Oncol Date: 2020-07-01 Impact factor: 31.777
Authors: D R Sullivan; C W Forsberg; L Ganzini; D H Au; M K Gould; D Provenzale; K S Lyons; C G Slatore Journal: Lung Cancer Date: 2016-08-16 Impact factor: 5.705
Authors: Donald R Sullivan; Christopher W Forsberg; Linda Ganzini; David H Au; Michael K Gould; Dawn Provenzale; Christopher G Slatore Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Jie Lin; Katherine A McGlynn; Corey A Carter; Joel A Nations; William F Anderson; Craig D Shriver; Kangmin Zhu Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-26 Impact factor: 4.254
Authors: Jimmy Ruiz; Antonius A Miller; Janet A Tooze; Sandrine Crane; William J Petty; Ajeet Gajra; Heidi D Klepin Journal: J Geriatr Oncol Date: 2018-07-10 Impact factor: 3.599
Authors: Claudia Trudel-Fitzgerald; Emily S Zevon; Ichiro Kawachi; Reginald D Tucker-Seeley; Laura D Kubzansky Journal: Psychol Med Date: 2020-12-03 Impact factor: 10.592